Key result
LMWH monotherapy serves as primary VTE treatment for ~25% of advanced cancer patients.
Why the study?
Evidence-based guidelines recommend LMWH monotherapy for cancer-associated VTE, but real-world first-line treatment strategies in advanced solid tumor patients were unclear.
What is the rate of adoption of low molecular weight heparin (LMWH) monotherapy for first-line treatment of venous thromboembolism in patients with advanced cancer?
Population
1,089 advanced lung, prostate, colon, or breast cancer patients with VTE diagnosed within 2 years after cancer diagnosis
Comparison
LMWH monotherapy versus other anticoagulants including warfarin and fondaparinux
Design
Observational analysis using administrative data from four HMOs with integrated delivery systems
Authors
Loading...
Low LMWH adoption in cancer-associated VTE should not yet change practice; leaves open research on implementation barriers and temporal trends.
Observational (n=1,089)
Yes
What is the rate of adoption of low molecular weight heparin (LMWH) monotherapy for first-line treatment of venous thromboembolism in patients with advanced cancer?
Adoption of guideline-recommended LMWH monotherapy as initial treatment for cancer-associated VTE was low (25%) but increased steadily between 2000 and 2007.
Delate et al. (2012) conducted an observational in Cancer-associated venous thromboembolism (n=1,089). Low molecular weight heparin (LMWH) monotherapy vs. Non-receipt of LMWH monotherapy was evaluated on Receipt of LMWH monotherapy as primary VTE treatment. Overall, 25% of 1,089 patients with advanced cancer and VTE received LMWH monotherapy as primary treatment, with utilization increasing from 18% in 2000 to 31% in 2007.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: